TABLE 3.
The correlation between the increase of metabolite levels and the reduction of clinical symptoms.
| Increase of metabolites | P subscore (r/p) | N subscore (r/p) | G subscore (r/p) | Total score (r/p) |
|---|---|---|---|---|
| LysoPE (20:5) | 0.17 (0.41) | −0.14 (0.50) | 0.17 (0.41) | 0.12 (0.56) |
| LysoPE (18:3) | 0.25 (0.23) | −0.11 (0.61) | 0.12 (0.56) | 0.12 (0.58) |
| LysoPE (16:1) | −0.18 (0.39) | 0.06 (0.79) | 0.09 (0.67) | −0.01 (0.97) |
| LysoPE (20:3) | 0.07 (0.73) | −0.10 (0.63) | 0.26 (0.21) | 0.16 (0.43) |
| LysoPE (22:5) | 0.03 (0.88) | −0.13 (0.55) | 0.15 (0.46) | 0.07 (0.73) |
| LysoPE (18:2) | 0.32 (0.12) | −0.09 (0.66) | 0.23 (0.26) | 0.22 (0.29) |
| LysoPE (22:1) | 0.14 (0.51) | −0.10 (0.62) | 0.11 (0.59) | 0.12 (0.56) |
| LysoPE (22:6) | −0.04 (0.85) | −0.37 (0.07) | −0.14 (0.51) | −0.18 (0.38) |
| LysoPE (22:0) | −0.05 (0.82) | −0.11 (0.59) | 0.01 (095) | −0.03 (0.88) |
| LysoPC(18:0) | 0.06 (0.79) | 0.05 (0.83) | −0.03 (0.91) | 0.04 (0.84) |
| LysoPC(22:6) | 0.04 (0.87) | −0.11 (0.60) | 0.06 (0.77) | 0.04 (0.84) |
| LysoPC(20:3) | 0.25 (0.22) | −0.02 (0.91) | 0.003 (0.99) | 0.08 (0.71) |
| LysoPC(20:4) | −0.14 (0.51) | −0.17 (0.43) | −0.15 (0.48) | −0.17 (0.41) |
| LysoPC(15:0) | −0.14 (0.50) | −0.23 (0.26) | −0.12 (0.56) | −0.20 (0.35) |
| LysoPC(22:4) | 0.17 (0.41) | −0.10 (0.65) | 0.02 (0.94) | 0.05 (0.81) |
| LysoPC(17:0) | −0.23 (0.26) | −0.16 (0.45) | −0.02 (0.94) | −0.13 (0.52) |
| LysoPC(14:0) | −0.10 (0.63) | −0.09 (0.67) | 0.09 (0.69) | −0.002 (0.99) |
| LysoPC(16:1) | −0.13 (0.53) | 0.06 (0.78) | 0.16 (0.46) | 0.08 (0.72) |
| LysoPC(18:3) | 0.43 (0.03)a | −0.04 (0.87) | 0.18 (0.40) | 0.26 (0.21) |
| LysoPC(20:2) | 0.43 (0.03)a | −0.04 (0.86) | 0.02 (0.94) | 0.14 (0.51) |
| LysoPC(22:2) | −0.14 (0.50) | −0.13 (0.52) | −0.08 (0.70) | −0.14 (0.50) |
| LysoPC(18:1) | 0.23 (0.26) | −0.33 (0.11) | −0.16 (0.46) | −0.10 (0.63) |
a
p < 0.05.